{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:34:18Z","timestamp":1771328058274,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Martin-Luther-Universit\u00e4t Halle-Wittenberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To assess the symptoms, quality of life and sexual well-being in patients with lower urinary tract symptoms due to benign prostatic hyperplasia LUTS\/BPH treated with pumpkin seed soft extract (PSE) in routine practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This noninterventional study included 130 men treated for up to 24\u00a0months. The International Prostate Symptom Score (IPSS) and related quality of life, Aging Males\u2019 Symptoms Scale (AMS), and International Index of Erectile Function (IIEF-5) were recorded. Descriptive statistical methods were applied. The mean with 95% confidence interval (CI) was calculated for the primary end point (change in IPSS after 12-month treatment).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Analysis at 12\u00a0months included 83 patients [mean (SD) age 65.2 (8.7)\u00a0years and IPSS (15.6 (3.4), IPSS-QoL 3.4 (0.9)]. AMS and IIEF-5 indicated mild or mild to moderate disorder regarding sexual well-being and erectile dysfunction, respectively. After 12\u00a0months, the mean IPSS change from baseline was\u2009\u2212\u20094.7 (95% CI\u2009\u2212\u20095.4 to\u2009\u2212\u20093.9), with 83% (95% CI 65.3 to 84.1) and 53% (95% CI 42.3 to 63.7) of the patients achieving reductions by at least 3 and 5 points, respectively. The proportion of patients with IPSS-QoL below 3 points (mostly satisfied) was 11% (9\/83) at baseline and rose to 62% (51\/83) and 73% (40\/55) at 12 and 24\u00a0months, respectively. AMS and IIEF-5 scores did not indicate a negative impact on sexual function during treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In men with a moderate LUTS suggestive of BPH, a low progression risk and an active sex life, treatment with pumpkin seed soft extract provided symptomatic relief, improved IPSS-QoL, and maintained sexual well-being.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>DRKS00010729, June 22, 2016.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-022-04036-w","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T15:02:58Z","timestamp":1653663778000},"page":"1769-1775","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study"],"prefix":"10.1007","volume":"40","author":[{"given":"Gerit","family":"Theil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Richter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tilo","family":"K\u00f6ttig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Patz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Heim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Krau\u00df","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miroslav","family":"Markov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Fornara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"4036_CR1","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306\u20131315","journal-title":"Eur Urol"},{"issue":"4\u20135","key":"4036_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.euf.2017.11.004","volume":"3","author":"C De Nunzio","year":"2017","unstructured":"De Nunzio C, Roehrborn CG, Andersson KE, McVary KT (2017) Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus 3(4\u20135):352\u2013363","journal-title":"Eur Urol Focus"},{"issue":"6","key":"4036_CR3","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.eururo.2004.12.013","volume":"47","author":"RC Rosen","year":"2005","unstructured":"Rosen RC, Giuliano F, Carson CC (2005) Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 47(6):824\u2013837","journal-title":"Eur Urol"},{"issue":"5\u20136","key":"4036_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000504611","volume":"104","author":"P Fornara","year":"2020","unstructured":"Fornara P, Madersbacher S, Vahlensieck W, Bracher F, Romics I et al (2020) Phytotherapy adds to the therapeutic armamentarium for the treatment of mild-to-moderate lower urinary tract symptoms in men. Urol Int 104(5\u20136):333\u2013342","journal-title":"Urol Int"},{"issue":"9","key":"4036_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1464-410X.2008.07498.x","volume":"101","author":"RO Fourcade","year":"2008","unstructured":"Fourcade RO, Th\u00e9ret N, Ta\u00efeb C (2008) Profile and management of patients treated for the first time for lower urinary tract symptoms\/benign prostatic hyperplasia in four European countries. BJU Int 101(9):1111\u20131118","journal-title":"BJU Int"},{"issue":"2","key":"4036_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.21037\/tau.2017.03.57","volume":"6","author":"J Gandhi","year":"2017","unstructured":"Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G et al (2017) The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol 6(2):295\u2013304","journal-title":"Transl Androl Urol"},{"key":"4036_CR7","first-page":"1","volume":"47","author":"A La Torre","year":"2014","unstructured":"La Torre A, Giupponi G, Duffy D et al (2014) Sexual dysfunction related to psychotropic drugs: a critical review. Part III: mood stabilizers and anxiolytic drugs. Pharmacopsychiatry 47:1\u20136","journal-title":"Pharmacopsychiatry"},{"issue":"7","key":"4036_CR8","first-page":"2261","volume":"39","author":"NR Bhatt","year":"2020","unstructured":"Bhatt NR, Davis NF, Witjes WP, Bjartell A, Caris C et al (2020) Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the evolution European registry. World J Urol 39(7):2261\u20132667","journal-title":"World J Urol"},{"key":"4036_CR9","volume-title":"Management of non-neurogenic male LUTs. EAU guidelines edition presented at the EAU annual congress, Milan","author":"S Gravas","year":"2021","unstructured":"Gravas S, Cornu JN, Gacci M et al (2021) Management of non-neurogenic male LUTs. EAU guidelines edition presented at the EAU annual congress, Milan. European Association of Urology, Europe"},{"issue":"7","key":"4036_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1055\/s-0035-1545906","volume":"81","author":"C Muller","year":"2015","unstructured":"Muller C, Bracher F (2015) Determination by GC-IT\/MS of phytosterols in herbal medicinal products for the treatment of lower urinary tract symptoms and food products marketed in Europe. Planta Med 81(7):613\u2013620","journal-title":"Planta Med"},{"issue":"2","key":"4036_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/jmf.2006.9.284","volume":"9","author":"M Gossell-Williams","year":"2006","unstructured":"Gossell-Williams M, Davis A, O\u2019Connor N (2006) Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil. J Med Food 9(2):284\u2013286","journal-title":"J Med Food"},{"issue":"3","key":"4036_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000094821","volume":"77","author":"YS Tsai","year":"2006","unstructured":"Tsai YS, Tong YC, Cheng JT, Lee CH, Yang FS et al (2006) Pumpkin seed oil and phytosterol-F can block testosterone\/prazosin-induced prostate growth in rats. Urol Int 77(3):269\u2013274","journal-title":"Urol Int"},{"issue":"4","key":"4036_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/BF02897676","volume":"14","author":"X Zhang","year":"1994","unstructured":"Zhang X, Ouyang JZ, Zhang YS, Tayalla B, Zhou XC et al (1994) Effect of the extracts of pumpkin seeds on the urodynamics of rabbits: an experimental study. J Tongji Med Univ 14(4):235\u2013238","journal-title":"J Tongji Med Univ"},{"key":"4036_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/1043-6618(95)80051-4","volume":"31","author":"AT Fahim","year":"1995","unstructured":"Fahim AT, Abd-el Fattah AA, Agha AM, Gad MZ (1995) Effect of pumpkin-seed oil on the level of free radical scavengers induced during adjuvant-arthritis in rats. Pharmacol Res 31:73\u201379","journal-title":"Pharmacol Res"},{"key":"4036_CR15","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4236\/pp.2018.96015","volume":"9","author":"S Heim","year":"2018","unstructured":"Heim S, S.S., Stier H, Mor\u00e9 MI, (2018) Uromedic\u00ae pumpkin seed derived \u03947-sterols, extract and oil inhibit 5\u03b1-reductases and bind to androgen receptor in vitro. Pharmacol Pharm 9:193","journal-title":"Pharmacol Pharm"},{"key":"4036_CR16","volume-title":"140 Effects of SPE-contained fatty acids on bladder muscarinic receptors and voiding function in rats, in International continence society meeting (ICS)","author":"Y Ito","year":"2012","unstructured":"Ito Y, Kojma N, Suzuki A, Kurokawa M, Yamada S (2012) 140 Effects of SPE-contained fatty acids on bladder muscarinic receptors and voiding function in rats, in International continence society meeting (ICS). Beijing, China"},{"issue":"2","key":"4036_CR17","doi-asserted-by":"publisher","first-page":"136","DOI":"10.4081\/aiua.2016.2.136","volume":"88","author":"R Damiano","year":"2016","unstructured":"Damiano R, Cai T, Fornara P, Franzese CA, Leonardi R et al (2016) The role of Cucurbita pepo in the management of patients affected by lower urinary tract symptoms due to benign prostatic hyperplasia: a narrative review. Arch Ital Urol Androl 88(2):136\u2013143","journal-title":"Arch Ital Urol Androl"},{"issue":"5","key":"4036_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s001310050432","volume":"40","author":"D Bach","year":"2000","unstructured":"Bach D (2000) Placebokontrollierte langzeittherapiestudie mit k\u00fcrbissamenextrakt bei BPH-bedingten miktionsbeschwerden. Der Urologe B 40(5):437\u2013443","journal-title":"Der Urologe B"},{"issue":"3","key":"4036_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000362903","volume":"94","author":"W Vahlensieck","year":"2015","unstructured":"Vahlensieck W, Theurer C, Pfitzer E, Patz B, Banik N et al (2015) Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int 94(3):286\u2013295","journal-title":"Urol Int"},{"key":"4036_CR20","volume-title":"The international consultation on benign prostatic hyperplasia 1991","author":"ATK Cockett","year":"1992","unstructured":"Cockett ATK (1992) The international consultation on benign prostatic hyperplasia 1991. World Health Organization, Paris, France"},{"issue":"1","key":"4036_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1477-7525-1-77","volume":"1","author":"I Daig","year":"2003","unstructured":"Daig I, Heinemann LAJ, Kim S, Leungwattanakij S, Badia X et al (2003) The aging males\u2019 symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 1(1):77","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"4036_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","volume":"11","author":"RC Rosen","year":"1999","unstructured":"Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pe\u00f1a BM (1999) Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11(6):319\u2013326","journal-title":"Int J Impot Res"},{"issue":"6","key":"4036_CR23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/iju.12741","volume":"22","author":"CG Roehrborn","year":"2015","unstructured":"Roehrborn CG, Casab\u00e9 A, Glina S, Sorsaburu S, Henneges C et al (2015) Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo. Int J Urol 22(6):582\u2013587","journal-title":"Int J Urol"},{"issue":"6","key":"4036_CR24","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.eururo.2007.03.034","volume":"51","author":"S Madersbacher","year":"2007","unstructured":"Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G (2007) The long-term outcome of medical therapy for BPH. Eur Urol 51(6):1522\u20131533","journal-title":"Eur Urol"},{"issue":"6","key":"4036_CR25","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/jsm.12525","volume":"11","author":"M Gacci","year":"2014","unstructured":"Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S et al (2014) Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 11(6):1554\u20131566","journal-title":"J Sex Med"},{"key":"4036_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2006.06.012","volume":"51","author":"A Hutchison","year":"2007","unstructured":"Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV (2007) The efficacy of drugs for the treatment of LUTS\/BPH, a study in 6 European countries. Eur Urol 51:207\u2013215","journal-title":"Eur Urol"},{"key":"4036_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.urology.2017.05.011","volume":"106","author":"K Eredics","year":"2017","unstructured":"Eredics K, Madersbacher S, Schauer I (2017) A relevant midterm (12 months) placebo effect on lower urinary tract symptoms and maximum flow rate in male lower urinary tract symptom and benign prostatic hyperplasia-a meta-analysis. Urology 106:160\u2013166","journal-title":"Urology"},{"issue":"7","key":"4036_CR28","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1111\/j.1464-410X.2009.08196.x","volume":"103","author":"J Barkin","year":"2009","unstructured":"Barkin J, Roehrborn CG, Siami P, Haillot O, Morrill B et al (2009) Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int 103(7):919\u2013926","journal-title":"BJU Int"},{"issue":"9","key":"4036_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijcp.13282","volume":"73","author":"RC Rosen","year":"2019","unstructured":"Rosen RC, Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH et al (2019) Evaluation of the impact of dutasteride\/tamsulosin combination therapy on libido in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH): a post hoc analysis of a prospective randomised placebo-controlled study. Int J Clin Pract 73(9):1\u20139","journal-title":"Int J Clin Pract"},{"key":"4036_CR30","doi-asserted-by":"publisher","first-page":"175628722092242","DOI":"10.1177\/1756287220922425","volume":"12","author":"P Abreu-Mendes","year":"2020","unstructured":"Abreu-Mendes P, Silva J, Cruz F (2020) Pharmacology of the lower urinary tract: update on LUTS treatment. Ther Adv Urol 12:1756287220922425","journal-title":"Ther Adv Urol"},{"issue":"6","key":"4036_CR31","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00345-020-03429-z","volume":"39","author":"HT Ayele","year":"2021","unstructured":"Ayele HT, Reynier P, Azoulay L, Platt RW, Cabaussel J et al (2021) Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study. World J Urol 39(6):2019\u20132028","journal-title":"World J Urol"}],"updated-by":[{"DOI":"10.1007\/s00345-022-04132-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T00:00:00Z","timestamp":1662163200000}}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-022-04036-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-022-04036-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T13:14:08Z","timestamp":1662210848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-022-04036-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["4036"],"URL":"https:\/\/doi.org\/10.1007\/s00345-022-04036-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00345-022-04132-x","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]},"assertion":[{"value":"25 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Electronic Supplementary Material not included in the original publication. Now, it has been included.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00345-022-04132-x","URL":"https:\/\/doi.org\/10.1007\/s00345-022-04132-x","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SH and YK are employees of Omega Pharma. BP is a consultant for Omega Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of the medical faculty ethics committee of Martin Luther University Halle-Wittenberg (number of ethical approval: 2016-06).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Consent to participate was given by the patients or their legal representatives.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consented to this publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}